Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 6/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25714649 | 0.93 | P2RY6 (0.46) | P2RY6P2RY2P2RY4P2RY14ENPP1 | |
| SCHEMBL17198808 | 0.93 | P2RY6 (0.58) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL17439374 | 0.91 | P2RY6 (0.61) | P2RY6P2RY2P2RY4P2RY14ENPP1 | |
| SCHEMBL17198814 | 0.89 | CYP3A4 (0.55) | P2RY6P2RY2P2RY4P2RY14ENPP1 | |
| SCHEMBL17198569 | 0.86 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL17198817 | 0.84 | CYP3A4 (0.54) | P2RY6P2RY2P2RY4P2RY14ENPP1 | |
| SCHEMBL17198816 | 0.83 | P2RY6 (0.54) | P2RY6P2RY2P2RY4P2RY14ENPP1 | |
| SCHEMBL17198624 | 0.83 | P2RY6 (0.57) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL17198556 | 0.82 | P2RY6 (0.55) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL17198298 | 0.80 | CYP3A4 (0.71) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | P2RY6 821/4885P2RY2 390/4885P2RY4 820/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | P2RY6 758/4885P2RY2 384/4885P2RY4 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.